Pharsight

Complera is owned by Gilead Sciences Inc.

Complera contains Emtricitabine; Rilpivirine Hydrochloride; Tenofovir Disoproxil Fumarate.

Complera has a total of 9 drug patents out of which 1 drug patent has expired.

Expired drug patents of Complera are:

Complera was authorised for market use on 10 August, 2011.

Complera is available in tablet;oral dosage forms.

Complera can be used as treatment of hiv infection.

The generics of Complera are possible to be released after 14 January, 2033.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080551	GILEAD SCIENCES INC	HIV inhibiting pyrimidines derivatives	Apr, 2023 (2 months from now)
US7125879	GILEAD SCIENCES INC	HIV inhibiting pyrimidines derivatives	Apr, 2025 (2 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101629	GILEAD SCIENCES INC	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile	Aug, 2022 (5 months ago)
US8716264	GILEAD SCIENCES INC	Compositions and methods for combination antiviral therapy	Jan, 2024 (11 months from now)
US9744181	GILEAD SCIENCES INC	Compositions and methods for combination antiviral therapy	Jan, 2024 (11 months from now)
US8592397	GILEAD SCIENCES INC	Compositions and methods for combination antiviral therapy	Jan, 2024 (11 months from now)
US9457036	GILEAD SCIENCES INC	Compositions and methods for combination antiviral therapy	Jan, 2024 (11 months from now)
US8841310	GILEAD SCIENCES INC	Combinations of a pyrimidine containing NNRTI with RT inhibitors	Dec, 2025 (2 years from now)
US10857102	GILEAD SCIENCES INC	Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate	Jan, 2033 (9 years from now)